Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Oklahoma State Supreme Court sides with J&J in opioid lawsuit

By Brian Buntz | November 10, 2021

Johnson & JohnsonThe Oklahoma State Supreme Court has overturned a 2019 opioid judgment against Johnson & Johnson (NYSE:JNJ) amounting to $465 million.

Five of the six Oklahoma Supreme Court’s justices dismissed the state’s case claiming that Johnson & Johnson breached its “public nuisance” laws in its marketing of prescription opioid drugs. “Oklahoma public nuisance law does not extend to the manufacturing, marketing and selling of prescription opioids,” the five justices wrote in their majority opinion.

Johnson & Johnson had argued that the judgment was flawed, arguing that the state did not show evidence that Johnson & Johnson caused a public nuisance in Oklahoma and that its claims violated core principles of due process.

Johnson & Johnson said in a press release that its prior sales of prescription opioids were “appropriate and responsible” but that the company has stopped selling such drugs as part of a larger effort to focus on new drug development.

Oklahoma’s litigation also had singled out Teva and Purdue Pharma — both of which had settled with the state before the Johnson & Johnson trial began.

Purdue reached a bankruptcy settlement in the U.S. Bankruptcy Court in White Plains, New York earlier this year.

In 2017, Oklahoma created a commission focusing on opioid abuse to study the epidemic and formulate responses to it. In addition to efforts to hold “distributors, manufacturers and businesses accountable,” the commission also sought to limit the use of opioids for treating acute pain.

Earlier this month, four drug companies won a similar lawsuit in California, convincing a judge that there was no evidence they were liable in the opioid epidemic. The four companies named in that suit included Johnson & Johnson, Teva (NYSE:TEVA), Allergan (NYSE:ABBV) and Endo (NSDQ:ENDP).

Tell Us What You Think! Cancel reply

Related Articles Read More >

Biogen logo
Biogen is scaling back space outside Boston
Fresenius Kabi
Fresenius Kabi plans to add 2D barcodes to its pharmaceutical portfolio
Dollars for drugs
Democrats’ drug pricing plan attracts pushback from Republicans
GBT/Pfizer
Pfizer to scoop up Global Blood Therapeutics for $5.4 billion 

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards